Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Continuous versus intermittent antibiotics for non‐cystic fibrosis bronchiectasis

Esta versión no es la más reciente

ver la versión actual 03 junio 2018

Información

DOI:
https://doi.org/10.1002/14651858.CD012733Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 26 julio 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Vías respiratorias

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Tim Donovan

    Correspondencia a: Medical and Sport Sciences, University of Cumbria, Lancaster, UK

    [email protected]

  • Lambert M Felix

    Postgraduate Medical Institute, Edge Hill University, Ormskirk, UK

  • James D Chalmers

    University of Dundee, Ninewells Hospital and Medical School, Dundee, UK

  • Stephen J Milan

    Lancaster Health Hub, Lancaster University, Lancaster, UK

  • Alexander G Mathioudakis

    Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK

  • Sally Spencer

    Postgraduate Medical Institute, Edge Hill University, Ormskirk, UK

Contributions of authors

All review authors contributed to the Background section. LF and SS contributed to the Methods section.

Sources of support

Internal sources

  • Edge Hill University, UK.

    Funded Lambert Felix to provide support for a series of reviews on bronchiectasis.

External sources

  • National Institute for Health Research (NIHR), UK.

    Evidence to guide care in adults and children with asthma, 13/89/14

Declarations of interest

J Chalmers: part of the EMBARC group that set research priorities in bronchiectasis. He also receives grant support from Pfizer, AstraZeneca and GlaxoSmithKline. In addition, he is part of an innovative medicines initiative consortium that includes Novartis and Basilea. He has participated in advisory boards for BayerHealthCare, Chiesi and Raptor Pharmaceuticals. He has received fees for speaking from Napp, AstraZeneca, BI and Pfizer. None of these conflicts of interest are related to the work of this review and are unrelated to the topic of the review.

T Donovan: none known.

L Felix: none known.

A Mathioudakis: none known.

S Milan: none known.

S Spencer: named co‐investigator on a study conducted to develop a series of reviews on bronchiectasis.

Acknowledgements

We would like to thank Edge Hill University for supporting this study. We would also like to thank the Cochrane Airways Group for its support.

Dr Chris Cates was the Editor for this review and commented critically on the review.

The Background and Methods sections of this protocol are based on a standard template used by Cochrane Airways.

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Airways. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

Version history

Published

Title

Stage

Authors

Version

2018 Jun 03

Continuous versus intermittent antibiotics for bronchiectasis

Review

Tim Donovan, Lambert M Felix, James D Chalmers, Stephen J Milan, Alexander G Mathioudakis, Sally Spencer

https://doi.org/10.1002/14651858.CD012733.pub2

2017 Jul 26

Continuous versus intermittent antibiotics for non‐cystic fibrosis bronchiectasis

Protocol

Tim Donovan, Lambert M Felix, James D Chalmers, Stephen J Milan, Alexander G Mathioudakis, Sally Spencer

https://doi.org/10.1002/14651858.CD012733

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Adult; Child; Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.